The Q2 miss and widening net loss, despite glaucoma growth, suggest near-term headwinds from retina weakness. Traders should watch for updates on international regulatory approvals and the headquarters relocation, which could impact Q3/Q4 retina revenue. The reaffirmed guidance provides a floor, but execution risk is elevated.
Price Chart
Executive Summary
IRIDEX reported Q2 2026 revenue of $12.6M, down 7% YoY and below the $13.6M consensus, with a GAAP net loss of $0.07/share versus consensus EPS of -$0.01. Glaucoma Cyclo G6 product revenue grew 19% YoY, but retina product revenue fell 19% due to Middle East disruptions and China headwinds. The company reaffirmed its full-year 2026 revenue guidance of $51M-$53M, but the overall miss on both top and bottom lines, combined with a net loss widening, makes this a bearish report.
Key Financial Metrics
Key Facts
- Total revenue of $12.6M, down 7% YoY from $13.6M and below the $13.6M consensus.
- GAAP net loss of $0.07 per share, wider than the $0.06 loss in the prior year and below consensus EPS of -$0.01.
- Cyclo G6 product family revenue grew 19% YoY to $3.9M, driven by 35% probe volume growth.
- Retina product revenue declined 19% YoY to $6.5M, attributed to Middle East disruptions and reduced China sell-through.
- Gross margin was relatively flat at 34.2% vs 34.5% in the prior year.
- Operating expenses decreased 5% YoY to $5.3M.
- Cash and cash equivalents were $4.7M, up $0.1M from the prior quarter.
- Full-year 2026 revenue guidance reaffirmed at $51M-$53M.
- Non-GAAP adjusted EBITDA loss was $0.4M vs a $21K gain in the prior year.
Financial Impact
Revenue miss of $1.0M (7% below consensus) and EPS miss of $0.06 (200% below consensus). Net loss widened by $0.3M YoY.
Risk Factors
- Continued weakness in retina product sales due to Middle East and China disruptions.
- Cash burn and reliance on working capital for inventory build ahead of headquarters relocation.
- Potential delays in international regulatory approvals impacting retina revenue recovery.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3347226 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 18, 2026 9w ago | 8-K | $0.7829 $0.6517 | ▲ +16.76% | ▲ +14.81% | $0.7500 (+4.20%) |
Aug 18, 2026 9w ago | Press Release | $0.7829 $0.6517 | ▲ +16.76% | ▲ +14.81% | $0.7500 (+4.20%) |
Jul 16, 2026 14w ago | 8-K | $0.9510 $0.8241 | ▲ +13.34% | ▲ +16.96% | $0.7500 (+21.14%) |
May 19, 2026 22w ago | 8-K | $1.00 $1.13 | ▲ +13.00% | ▲ +12.26% | $0.7500 (−25.00%) |
Apr 24, 2026 26w ago | DEFA14A | $1.08 $1.04 | ▼ −3.70% | ▼ −8.66% | $0.7500 (−30.56%) |
Apr 7, 2026 28w ago | Press Release | $1.03 $1.05 | ▲ +1.94% | ▼ −6.60% | $0.7500 (−27.18%) |
Mar 26, 2026 30w ago | Press Release | $0.9900 $1.08 | ▲ +9.09% | ▼ −3.65% | $0.7500 (−24.24%) |
Mar 12, 2026 32w ago | Press Release | $1.30 $1.03 | ▼ −20.77% | ▼ −24.36% | $0.7500 (−42.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers